BioPharma Dive July 28, 2021
Kristin Jensen

Dive Brief:

  • Ring Therapeutics, a startup developing a new method to deliver gene therapy products, has raised $117 million in a Series B financing.
  • The startup creator that formed Moderna, Flagship Pioneering, is also the founding investor for Ring. Flagship participated in the Series B round alongside other firms including Invus, Altitude Life Science Ventures, Partners Investment and UPMC Enterprises.
  • Ring said it will use the money to advance gene therapies that harness harmless anelloviruses present in the human body. The company says it has thousands of candidates for anello-based vectors that can be used to deliver therapies, though its work remains in early stages.

Dive Insight:

With Ring, Flagship is looking for another breakout star in the...

Today's Sponsors

Transcarent
SalesSparx
Canton & Company

Today's Sponsors

Oscar
Curation Health

Today's Sponsor

TripleTree

 
Topics: Biotechnology, Investments, Pharma / Biotech, Trends
Rune Labs Lands $22.8M to for Neurology Precision Medicine Platform
Rome Therapeutics raises $77m for junk DNA-targeting drugs
Lightstone Ventures Raises $375M Fund to Invest in Early Stage Biotech and Medtech Companies
France’s biotech ecosystem is primed for growth – it’s time to feed it
MIT study finds more than 1m potential genome-editing tools in microbes